PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:PBH - US74112D1019 - Common Stock
65.3 USD
+1.13 (+1.76%)
65.3 USD
0 (0%)
Overall PBH gets a fundamental rating of 6 out of 10. We evaluated PBH against 190 industry peers in the Pharmaceuticals industry. PBH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. PBH has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year PBH was profitable.
PBH had a positive operating cash flow in the past year.
Of the past 5 years PBH 4 years were profitable.
In the past 5 years PBH always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.83%, PBH belongs to the top of the industry, outperforming 86.84% of the companies in the same industry.
Looking at the Return On Equity, with a value of 11.00%, PBH belongs to the top of the industry, outperforming 85.79% of the companies in the same industry.
PBH's Return On Invested Capital of 7.88% is amongst the best of the industry. PBH outperforms 85.79% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PBH is below the industry average of 12.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROIC | 7.88% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
With an excellent Profit Margin value of 18.09%, PBH belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
In the last couple of years the Profit Margin of PBH has grown nicely.
Looking at the Operating Margin, with a value of 31.00%, PBH belongs to the top of the industry, outperforming 94.21% of the companies in the same industry.
In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
PBH's Gross Margin of 56.10% is fine compared to the rest of the industry. PBH outperforms 67.89% of its industry peers.
PBH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
PBH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
PBH has less shares outstanding than it did 1 year ago.
PBH has less shares outstanding than it did 5 years ago.
The debt/assets ratio for PBH has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.61 indicates that PBH is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.61, PBH is doing good in the industry, outperforming 63.68% of the companies in the same industry.
The Debt to FCF ratio of PBH is 3.97, which is a good value as it means it would take PBH, 3.97 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 3.97, PBH belongs to the best of the industry, outperforming 86.32% of the companies in the same industry.
PBH has a Debt/Equity ratio of 0.55. This is a neutral value indicating PBH is somewhat dependend on debt financing.
PBH has a worse Debt to Equity ratio (0.55) than 66.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Altman-Z | 2.61 |
ROIC/WACC0.89
WACC8.85%
2.3 Liquidity
A Current Ratio of 3.70 indicates that PBH has no problem at all paying its short term obligations.
PBH has a Current ratio of 3.70. This is comparable to the rest of the industry: PBH outperforms 56.84% of its industry peers.
A Quick Ratio of 2.51 indicates that PBH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.51, PBH is in line with its industry, outperforming 51.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.15% over the past year.
The Earnings Per Share has been growing by 8.88% on average over the past years. This is quite good.
The Revenue has decreased by -0.02% in the past year.
Measured over the past years, PBH shows a small growth in Revenue. The Revenue has been growing by 3.39% on average per year.
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
3.2 Future
The Earnings Per Share is expected to grow by 4.13% on average over the next years.
Based on estimates for the next years, PBH will show a small growth in Revenue. The Revenue will grow by 1.15% on average per year.
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PBH is valuated correctly with a Price/Earnings ratio of 14.32.
PBH's Price/Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 86.84% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.25, PBH is valued a bit cheaper.
PBH is valuated correctly with a Price/Forward Earnings ratio of 13.34.
Based on the Price/Forward Earnings ratio, PBH is valued cheaply inside the industry as 83.68% of the companies are valued more expensively.
PBH's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.98.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.32 | ||
| Fwd PE | 13.34 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 87.37% of the companies listed in the same industry.
88.42% of the companies in the same industry are more expensive than PBH, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.29 | ||
| EV/EBITDA | 10.8 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of PBH may justify a higher PE ratio.
PEG (NY)8.73
PEG (5Y)1.61
EPS Next 2Y3.96%
EPS Next 3Y3.41%
5. Dividend
5.1 Amount
No dividends for PBH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
65.3
+1.13 (+1.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners108.83%
Inst Owner Change1.62%
Ins Owners1.31%
Ins Owner Change0.82%
Market Cap3.14B
Revenue(TTM)1.11B
Net Income(TTM)200.84M
Analysts84
Price Target79.05 (21.06%)
Short Float %4.5%
Short Ratio4.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.61%
Min EPS beat(2)-5.96%
Max EPS beat(2)9.18%
EPS beat(4)3
Avg EPS beat(4)2.04%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)5
Avg EPS beat(8)-0.36%
EPS beat(12)7
Avg EPS beat(12)-46.48%
EPS beat(16)11
Avg EPS beat(16)-33.78%
Revenue beat(2)1
Avg Revenue beat(2)0.1%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)5.55%
Revenue beat(4)3
Avg Revenue beat(4)0.5%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.15%
Revenue beat(16)9
Avg Revenue beat(16)0.5%
PT rev (1m)0%
PT rev (3m)-7.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.36%
EPS NY rev (1m)0%
EPS NY rev (3m)0.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.32 | ||
| Fwd PE | 13.34 | ||
| P/S | 2.83 | ||
| P/FCF | 12.29 | ||
| P/OCF | 11.92 | ||
| P/B | 1.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.8 |
EPS(TTM)4.56
EY6.98%
EPS(NY)4.9
Fwd EY7.5%
FCF(TTM)5.31
FCFY8.14%
OCF(TTM)5.48
OCFY8.39%
SpS23.1
BVpS37.96
TBVpS-20.68
PEG (NY)8.73
PEG (5Y)1.61
Graham Number62.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROCE | 10.41% | ||
| ROIC | 7.88% | ||
| ROICexc | 8.17% | ||
| ROICexgc | 70.59% | ||
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% | ||
| FCFM | 23% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 27.11% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | 7.8 | ||
| Cash Conversion | 70.49% | ||
| Profit Quality | 127.19% | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 | ||
| Altman-Z | 2.61 |
F-Score7
WACC8.85%
ROIC/WACC0.89
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
EBIT growth 1Y5.81%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year6.22%
EBIT Next 3Y3.43%
EBIT Next 5Y3.05%
FCF growth 1Y18.43%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y17.36%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PBH.
Can you provide the valuation status for PRESTIGE CONSUMER HEALTHCARE?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
What is the profitability of PBH stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
What is the expected EPS growth for PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.64% in the next year.